[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"electroencephalography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:electroencephalography":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,71,118,140,160,186,210,242,259,292,317,348,373,397,421],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645177","cannabis-observations-on-brain-waves-retrieval-and-attention-experiment-4-100645177",false,"NCT07679581","Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4","Cannabis and Memory","COBRA 4","1. Must be between the ages of 21 and 40 and provide informed consent;\n2. Must be right-handed (Laterality Quotient \\> 60 on Edinburgh Handedness Inventory - Short Form136);\n3. Heavy users (HU) in Experiments 1, 2, 3, and 4:\n\n   1. Must use cannabis at least 4 days during the month;\n   2. Must be a cannabis user for at least a year;\n4. Non-users (NU) in Experiment 2:\n\n   1. Must not have used cannabis for prior 6 months;\n   2. Must have at least one episode of lifetime cannabis use;\n5. Must self-report not using other illicit recreational drugs (e.g., cocaine, benzodiazepines (non-prescription), opiates (non-prescription), MDMA, sedatives, or methamphetamine) in the past 30 days, during the Pre-Screening;\n6. Must not test positive on a urine toxicology test for drugs of abuse at the Baseline Appointment (TDS);\n7. Must not be using psychotropic medications, however anti-depressant, non-benzodiazepine anti-anxiety, and ADHD medications are ok. ADHD medication users must be willing to abstain from ADHD medication use on appointment days; ADHD medications, even extended-release forms, are short acting and medication\" holidays\" (e.g., on weekends and holidays) are routine in individuals prescribed ADHD medications, without adverse effects.\n8. Must not be a regular nicotine user (≤4 days per week; cigarette, E-cigs, or smokeless);\n9. Must not have used caffeine or nicotine (cigarette, E-cigs, or smokeless) for 4 hours;\n10. Must have a breath alcohol level of 0 at screening (to sign consent form);\n11. Must not be actively seeking or in treatment for any substance use disorder (drug use levels will be carefully monitored via Timeline Follow Back (TLFB) throughout the study to assess any confounding influences of drug or alcohol use;\n12. Female subjects must not be or trying to become pregnant (as indicated by a pregnancy test \\& screening form administered at Baseline);\n13. Must not be in treatment for psychotic disorder or bipolar disorder; or have a history with these disorders;\n14. Must not have any physical characteristics (e.g., thick hair, head size exceeding the limit of the net, dyed hair) or experience any technical difficulties during testing that result in a poor-quality EEG recording.\n15. Participants in Experiment 4 a. Must not have participated in Experiment 3",true,"ALL","21 Years","40 Years",{"count":22,"type":23},64,"ESTIMATED","OBSERVATIONAL","This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of two different strains of cannabis flower one day and while not intoxicated another day. Event-related potentials (ERPs) are measured via electroencephalogram (EEG) during the recognition memory task. Blood is collected to quantify THC and CBD exposure. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.",[27,28,29],"Cannabis","Memory","Electroencephalography",[27,28,29],"RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2025-12-10",{"date":39,"type":23},"2027-05-31",{"name":41,"class":42},"L. Cinnamon Bidwell","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100441986","a-machine-learning-approach-for-predicting-tdcs-treatment-outcomes-of-adolescents-with-autism-spectrum-disorders-100441986","NCT05035511","A Machine Learning Approach for Predicting tDCS Treatment Outcomes of Adolescents With Autism Spectrum Disorders","Inclusion Criteria:\n\n* Individuals who are confirmed by a clinical psychologist based on the Diagnostic and Statistical Manual of Mental Disorders-5th Ed (DSM-V) criteria of Autism spectrum disorder and structured interview with their parents or primary caregivers on their developmental history using the Autism Diagnostic Interview-Revised (ADI-R).\n* Individuals with intelligence quotient above 60.\n* Individuals who demonstrate the ability to comprehend testing and stimulation instructions.\n\nExclusion Criteria:\n\n* Individuals with severe motor dysfunctions that would hinder their participation, and those with history of other neurological and psychiatric disorders and head trauma, or on psychiatric medication will be excluded from the study","12 Years","22 Years",{"count":53,"type":23},90,"INTERVENTIONAL",[56],"NA","Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by disturbances in communication, poor social skills, and aberrant behaviors. Particularly detrimental are the presence of restricted and repetitive stereotyped behaviors and uncontrollable temper outbursts over trivial changes in the environment, which often cause emotional stress for the children, their families, schools and neighborhood communities.\n\nFundamental to these cognitive and behavioral problems is the disordered cortical connectivity and resultant executive dysfunction that underpin the use of effective strategies to integrate information across contexts. Brain connectivity problems affect the rate at which information travels across the brain. Slow processing speed relates to a reduced capacity of executive function to recall and formulate thoughts and actions automatically, with the result that autistic children with poor processing speed have great difficulty learning or perceiving relationships across multiple experiences. In consequence, these children compensate for the impaired ability to integrate information from the environment by memorizing visual details or individual rules from each situation. This explains why children with autism tend to follow routines in precise detail and show great distress over seemingly trivial changes in the environment.\n\nTo date, there is no known cure for ASD, and the disorder remains a highly disabling condition. Recently, a non-invasive brain stimulation technique, transcranial direct current Stimulation (tDCS) has shown great promise as a potentially effective and costeffective tool for reducing core symptoms such as anxiety, aggression, impulsivity, and inattention in patients with autism. This technique has been shown to modify behavior by inducing changes in cortical excitability and enhancing connectivity between the targeted brain areas. However, not all ASD patients respond to this intervention the same way and predicting the behavioral impact of tDCS in patients with ASD remains a clinical challenge. This proposed study thus aims to address these challenges by determining whether resting-state EEG and clinical data at baseline can be used to differentiate responders from non-responders to tDCS treatment. Findings from the study will provide new guidance for designing intervention programs for individuals with ASD.",[59,60,29,61],"Transcranial Direct Current Stimulation","Autistic Disorders Spectrum","Machine Learning","2026-06-21",{"date":64,"type":35},"2026-06-24",{"date":66,"type":35},"2022-01-05",{"date":68,"type":23},"2026-12-31",{"name":70,"class":42},"The Hong Kong Polytechnic University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":82,"conditions":83,"keywords":96,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100629619","non-invasive-detection-and-preservation-of-neurocognitive-signals-in-the-peri-death-period-using-brain-computer-interface-and-artificial-intelligence-100629619","NCT07477028","Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence","Feasibility of Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence: A Prospective Observational Study (NeuroCogPresv)","NeuroCogPresv","Inclusion Criteria:\n\n1. Adults ≥18 years with terminal illness or severe acute trauma\n2. Do-not-resuscitate (DNR\u002FDNI) order in place\n3. Surrogate decision-maker available and willing to provide informed consent\n4. Expected survival ≤7 days (physician estimate)\n\nExclusion Criteria:\n\n1. Brain death already declared \\> 24 hours prior to enrollment\n2. Contraindication to EEG\u002FBCI headset placement (e.g., severe scalp injury)\n3. Patient lacks a legally authorized representative","18 Years",{"count":81,"type":23},20,"Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power, cross-frequency coupling, and distinct spreading depolarization waves. This prospective, observational feasibility study utilizes rapid-deployment, high-density, noninvasive BCI hardware paired with proprietary AI analytics to detect, classify, and securely archive these terminal neurocognitive signals.\n\nObjectives: (1) Quantify transient gamma-band activity and cross-frequency connectivity post-clinical death; (2) Validate the efficacy of machine learning models for real-time signal classification in high-noise clinical environments; (3) Establish a highly secure, encrypted bio-informational archive of peri-life EEG data.\n\nDesign: Prospective, open-label, multicenter, observational cohort (n\\>20).",[84,85,86,87,88,89,29,90,91,92,93,28,94,95],"Terminal Illness","End-of-Life Care","Death","Brain Death","Death Anxiety","Consciousness","Gamma Oscillations","Near-Death Phenomena","Cognitive","Cognition","EEG","Severe Acute Trauma",[97,98,99,86,90,93,89,100,101,102,28,103,104,105,106],"AI","BCI","Brain Computer Interface","Pefi-death","Brain death","Reservation","Life","Life experience","Transfer","Convergence","NOT_YET_RECRUITING","2026-03-12",{"date":110,"type":35},"2026-03-17",{"date":112,"type":23},"2026-09-01",{"date":114,"type":23},"2035-09-30",{"name":116,"class":117},"Noah Tech, Corp.","INDUSTRY",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":18,"minAge":125,"maxAge":50,"enrollmentInfo":126,"targetDuration":4,"studyType":54,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":43},"100583733","transcranial-direct-current-stimulation-in-children-with-autism-spectrum-disorder-100583733","NCT06880159","Transcranial Direct Current Stimulation in Children With Autism Spectrum Disorder","Effects of Transcranial Direct Current Stimulation (tDCS) for Enhancing Cognitive Function in Children With Autism Spectrum Disorder","Inclusion Criteria:\n\n* being 8-12 years old\n* diagnosed with ASD given by registered psychiatrists or clinical psychologists according to the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) criteria of ASD\n* IQ score above 60\n* able to communicate in Chinese\n\nExclusion Criteria:\n\n* with severe motor dysfunctions\n* history of other neurological and psychiatric disorders or head trauma","8 Years",{"count":53,"type":23},[56],"Background: Transcranial Direct Current Stimulation (tDCS) is a form of non-invasive brain stimulation that has aroused increased interests in the past decade. Not only that it is transient with little side-effects, and can be well-tolerated by children, it is also affordable and readily accessible, making it an appealing treatment option for autism spectrum disorder (ASD).\n\nObjective: (1) To assess the therapeutic effects of tDCS when combined with cognitive training for 10 consecutive weekdays on improving cognitive processing in children with ASD, relative to control group receiving sham-stimulation, and (2) to evaluate the associated neural mechanisms underlying the treatment effect of tDCS on children with ASD.\n\nMethods: To assess the therapeutic effects of tDCS, 90 adolescents with ASD (age 6-12 years) will be randomly assigned to active- (n=45), or sham- (n=45) tDCS groups. Twenty-minute sessions of tDCS stimulation to the left dorsolateral prefrontal cortex (DLPRC) will be provided on 10 consecutive weekdays, in conjunction with cognitive training exercises. Participants with a head circumference of less than 53 cm will receive 1.0 mA of stimulation, while those with a circumference of 53 cm or greater will receive 1.5 mA. EEG, fNIRS and neuropsychological tests will be administered before, immediately after, and 2 months after the series of tDCS sessions.\n\nHypothesis: The investigators hypothesize that children with ASD who are randomly assigned to receive a montage of prefrontal tDCS, with cathode (inhibitory) placed over left DLPFC and anode (excitatory) over right supraorbital region) will evidence greater improvement in executive function (primary outcome) than children with ASD who are randomly assigned to receive sham-tDCS.\n\nIn addition to testing the primary clinical outcome, stated above, in planned exploratory analyses, the investigators will also examine the effects of tDCS on secondary outcome measures of cognitive function, including information processing speed, working memory, inhibitory control, and cognitive flexibility; and conduct exploratory mediation analyses to better understand the potential neurophysiological factors underlying the therapeutic effects of tDCS. This will include E\u002FI ratio as exploratory mediator variables. As these secondary analyses are exploratory, the investigators will report them as such in presentations and published papers, and the investigators will not draw definitive conclusions from them. Rather, they will be used to better understand the potential impact of tDCS and the mechanisms underlying impact, and to inform future research.",[130,131,29],"Autism Spectrum Disorder (ASD)","Transcranial Direct Current Stimulation (tDCS)","2026-02-04",{"date":134,"type":35},"2026-02-06",{"date":136,"type":35},"2025-09-01",{"date":138,"type":23},"2028-06",{"name":70,"class":42},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":18,"minAge":50,"maxAge":19,"enrollmentInfo":147,"targetDuration":4,"studyType":54,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":43},"100537041","cumulative-and-booster-effects-of-multisession-prefrontal-tdcs-in-asd-adolescents-100537041","NCT06272669","Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents","Cumulative and Booster Effects of Multisession Prefrontal tDCS on Cognitive and Social Impairments in Adolescents With Autism Spectrum Disorder","Inclusion Criteria:\n\n* Individuals who are confirmed by a clinical psychologist based on the Diagnostic and Statistical Manual of Mental Disorders-5th Ed (DSM-V) criteria of Autism spectrum disorder and structured interview with their parents or primary caregivers on their developmental history using the Autism Diagnostic Interview-Revised (ADI-R).\n\nExclusion Criteria:\n\n* Individuals without a confirmed diagnosis from the clinical psychologist, with a history of other neurological and psychiatric disorders and head trauma, or on psychiatric medication will be excluded from the study.",{"count":53,"type":23},[56],"Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by disturbances in communication, poor social skills, and aberrant behavior. To date, ASD has no known cure, and the disorder remains a highly disabling condition. Recently, transcranial direct-current stimulation (tDCS), a non-invasive brain stimulation technique, has shown great promise as a potentially effective and cost-effective tool for reducing the core symptoms in patients with autism, such as anxiety, aggression, impulsivity, and inattention. Although the preliminary findings in patients with ASD are encouraging, it remains to be determined whether this experimental data can translate into benefits in real life. Further studies are needed to determine the factors that can lengthen the therapeutic effects or cognitive benefits of tDCS, and to determine possible risk factors associated with relapse in patients with ASD. Booster sessions of tDCS is an important component of treatment planning and prognosis and may promote better outcomes to control for resurgence of symptoms. This study has three aims. First, the investigators aim to evaluate the therapeutic effects of tDCS on improving cognitive function in patients with ASD. Second, the investigators aim to better understand the neural mechanisms underlying the neuro-enhancing effects of tDCS in patients with ASD. Third, the investigators aim to assess the effectiveness of booster treatment cycles of tDCS for enhancing cognitive and social functions in individuals with ASD.",[59,151,29],"Autistic Spectrum Disorder","2025-11-19",{"date":154,"type":35},"2025-11-21",{"date":156,"type":35},"2022-06-02",{"date":158,"type":23},"2026-12",{"name":70,"class":42},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":18,"minAge":50,"maxAge":19,"enrollmentInfo":167,"targetDuration":4,"studyType":54,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":185,"locationsCount":43},"100477059","cumulative-and-booster-effects-of-multisession-prefrontal-transcranial-direct-current-stimulation-in-adolescents-with-asd-100477059","NCT05492032","Cumulative and Booster Effects of Multisession Prefrontal Transcranial Direct Current Stimulation in Adolescents With ASD","Cumulative and Booster Effects of Multisession Prefrontal Transcranial Direct-Current Stimulation (tDCS) on Cognitive and Social Impairments in Adolescents With Autism Spectrum Disorder","Inclusion Criteria:\n\n* Individuals who are confirmed by a clinical psychologist based on the Diagnostic and Statistical Manual of Mental Disorders-5th Ed (DSM-V) criteria of Autism spectrum disorder and structured interview with their parents or primary caregivers on their developmental history using the Autism Diagnostic Interview-Revised (ADI-R).\n* Individuals with ASD who are comorbid with ADHD symptoms will be included if they were willing to abstain from the use of these medications at least 96 hours before the commencement, until the completion, of the treatment.\n* In view of the fact that neuroadaptation to antipsychotics typically occurs within six months, potential participants who are prescribed antipsychotic medications will only be included if the dosage of the medication remained unchanged for six months or more before the experimental period.\n\nExclusion Criteria:\n\n* Individuals without a confirmed diagnosis from the clinical psychologist, with a history of other neurological and psychiatric disorders and head trauma, or on psychiatric medication will be excluded from the study.\n* In view of the possibility of seizure induction by tDCS, potential ASD participants comorbid with epilepsy will be excluded.\n* Potential participants comorbid with mood or anxiety disorders will also be excluded.",{"count":168,"type":23},150,[56],"Autism spectrum disorder (ASD) is a pervasive and lifelong developmental disorder that currently affects 1 in 54 children. Individuals with autism are often severely impaired in communication, social skills, and cognitive functions. Particularly detrimental characteristics typical of ASD include the inability to relate to people and the display of repetitive stereotyped behaviors and uncontrollable temper outbursts over trivial changes in the environment, which often cause emotional stress for the children, their families, schools and neighborhood communities. To date, there is no cure for ASD, and the disorder remains a highly disabling condition. Recently, transcranial direct current stimulation (tDCS), a noninvasive neuromodulation technique, has shown great promise as an effective and cost-effective tool for reducing core symptoms, such as anxiety, aggression, impulsivity, and poor social communication, in patients with autism. Although the empirical findings in patients with ASD are encouraging, it remains to be determined whether these experimental data can be translated into real-world benefits. An important next step is to better understand the factors affecting the long-term efficacy of tDCS treatment - in particular, the possible risk factors associated with relapse in patients with ASD and the role of booster session tDCS as an add-on treatment to induce long-lasting neuroplastic effects in ASD.",[59,151,29,172],"Booster Effects",[174,175,176,177,94,178,179,180],"Autism","ASD","tDCS","Treatment outcome","E\u002FI ratio","Booster effects","Cognitive function",{"date":182,"type":35},"2025-11-26",{"date":156,"type":35},{"date":68,"type":23},{"name":70,"class":42},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":54,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100534305","remifentanil-effect-on-burst-suppression-ratio-100534305","NCT06237101","Remifentanil Effect on Burst Suppression Ratio","Influence of Variable Plasma Concentrations of Remifentanil on Burst Suppression (BS) Event Rate in Electroencephalographic (EEG) Recordings of Human Subjects Undergoing Total Intravenous General Anesthesia (TIVA) Under Propofol","Inclusion Criteria:\n\n* American Society of Anesthesiology I or II\n* Elective surgery of low or intermediate risk\n\nExclusion Criteria:\n\n* Neurological disease\n* Psychiatric disease\n* Use of psychoactive drugs or opioids\n* Altered basal state of consciousness\n* Allergy to propofol\n* Body mass index \\> 35 kg\u002Fm2\n* Pre-existing renal, cardiac and\u002For hepatic dysfunction\n* Patient's refusal to participate","60 Years",{"count":81,"type":23},[56],"The goal of this clinical trial is to determine whether remifentanil has a facilitating effect on the generation of burst suppression by propofol in adult patients (18-60 years) candidates for elective surgery who require remifentanil and American Society of Anesthesiology (ASA) classification I or II. The main question it aims to answer are:\n\n• To determine whether remifentanil has a facilitating effect on the generation of burst suppression by propofol.\n\nParticipants will undergo general anesthesia with remifentanil and propofol sequentially. After loss of consciousness, remifentanil will be adjusted to a medium or high concentration randomly and it will be determined at what concentration of propofol the burst suppressions are generated.\n\nThen, the concentrations of propofol that generate burst suppression associated with either a medium or high concentration of remifentanil will be compared.",[198,29,199],"Anesthesia, Intravenous","Burst Suppression","2025-11-17",{"date":202,"type":35},"2025-11-20",{"date":204,"type":35},"2024-03-01",{"date":206,"type":23},"2026-09-30",{"name":208,"class":42},"University of Chile",2,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":18,"minAge":217,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":54,"phases":221,"briefSummary":222,"conditions":223,"keywords":231,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":43},"100571845","integrative-medicine-in-pain-management-in-sickle-cell-disease-20-100571845","NCT06725550","Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0","Integrative Medicine in Pain Management in Sickle Cell Disease: Assessing the Clinical Efficacy and Neurobiological Impact With Acupuncture, 2.0","Inclusion Criteria:\n\n* Any gender\n* 14-17 (Adolescents) and 18-80 (Adults) years old\n* Right-handed\n* Either outpatient or inpatient or status changing between each other\n* Have been diagnosed with SCD (includes but not limited to SS, SC or other type) and experiencing chronic pain in the past 6 months or vaso-occlusive crisis (VOC) in the past 12 months.\n* Analgesic therapy prescribed by primary hematologists (or physicians for emergency or primary care) including pain-relieving medications (e.g. Morphine, coderin, Fentanyl, Oxycodone), Hydroxyurea (e.g. Droxia, Hydrea, Siklos), L-glutamine oral powder (Endari), Crizanlizumab (Adakveo), Voxelotor (Oxbryta), and\u002For other palliative treatment allowed, not required.\n* Willing to limit the current and the introduction of any new medications or treatment modalities for control of pain symptoms during the study visits.\n* Able to travel to the study site for participating scheduled visits (questionnaires, QST, EEG and MRI) and receive acupuncture treatments up to two times weekly for 5 weeks as scheduled.\n* We will recruit without regard to ethnicity, however, due to the genetic nature of SCD, subjects will primarily be African-American or of African descent, although there are individuals with SCD who come from Hispanic, southern European, Middle Eastern, or Asian Indian backgrounds. The ethnic distribution in our prior studies is 95% Black\u002FAfrican American with 5% Hispanic or Latino (of any race). As these are minority groups many individuals may be from lower income situations.\n* Fluent in English and capable of giving written informed consent.\n\nExclusion Criteria:\n\n* Subjects with Covid-19 suspicion or confirmation\n* Recent\u002Fongoing alternative pain management with acupuncture or acupuncture-related techniques within the last 6-months.\n* Presence of a known coagulation abnormality: Thrombocytopenia (mild thrombocytopenia with a platelets range of 51,000-100,000\u002Ful will be further evaluated for inclusion consideration), or bleeding diathesis that may preclude the safe use of acupuncture.\n* Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain or any other chronic pain condition with pain greater than sickle pain.\n* Diseases\u002Fconditions history includes but not limited to:\n\n  * head injury with substantial loss of consciousness\n  * peripheral neuropathy of known cause that interferes with activities of daily living\n  * known non-SCD related Severe psychiatric illnesses (e.g. current schizophrenia, major depression with suicidal ideation).\n  * significant visual, motor, or auditory impairment that would interfere with ability to perform study visits-related activities\n* Medication:\n\nRecent (30 days) initiation or dose adjustment of stimulant medications, such as those used to treat ADD\u002FADHD (e.g., amphetamine\u002Fdextroamphetamine \\[Adderall®\\], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil).\n\n* Contraindications to MRI scans includes but are not limited to: surgical clips, surgical staples, metal implants, cardiac rhythmic disorders, seizure disorders, and certain metallic dental material will not be scheduled for MRI visits.\n* History vascular surgery in lower limbs or current lower limb vascular dysfunction will not receive conditioned pressure pain stimuli in the lower limb.\n* Subjects with Worker's Compensation, Workman's Compensation, civil litigation or disability claims pertinent to the subject's sickle disease; current involvement in out-of-court settlements for claims pertinent to the subject's sickle disease; or currently receiving monetary compensation as a result of any of the above.\n* Participation of other studies: Concurrent participation in other therapeutic trials with overlapping research purposes.\n* Pregnant or nursing.","14 Years","80 Years",{"count":220,"type":23},120,[56],"The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.",[224,225,226,227,228,229,29,230],"Sickle Cell Disease","Pain","Acupuncture","Quantitative Sensory Testing","Magnetic Resonance Imaging","Circulating Biomarkers","Functional Near-infrared Spectroscopy",[232,225,226,227,228,229,29,230],"Sickle cell disease","2025-10-15",{"date":235,"type":35},"2025-10-20",{"date":237,"type":35},"2025-08-25",{"date":239,"type":23},"2030-08-30",{"name":241,"class":42},"Indiana University",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":18,"minAge":50,"maxAge":51,"enrollmentInfo":248,"targetDuration":4,"studyType":54,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":258,"locationsCount":43},"100583592","resting-state-functional-connectivity-as-a-predictor-of-tdcs-effects-in-adolescents-with-autism-spectrum-disorder-100583592","NCT06878326","Resting-State Functional Connectivity as a Predictor of tDCS Effects in Adolescents With Autism Spectrum Disorder","Inclusion Criteria:\n\n* being 12-22 years old\n* diagnosed with ASD given by registered psychiatrists or clinical psychologists according to the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) criteria of ASD\n* able to communicate in Chinese\n\nExclusion Criteria:\n\n* without a confirmed diagnosis from the clinical psychologist\n* history of other neurological and psychiatric disorders and head trauma\n* on psychiatric medication",{"count":53,"type":23},[56],"Background: Transcranial Direct Current Stimulation (tDCS) is a form of non-invasive brain stimulation that has aroused increased interests in the past decade. Not only that it is transient with little side-effects, and can be well-tolerated by children, it is also affordable and readily accessible, making it an appealing treatment option for autism spectrum disorder (ASD).\n\nObjective: (1) To evaluate the therapeutic effects of tDCS on improving cognitive function in patients with ASD, (2) to better understand the neural mechanisms underlying the neuromodulation effects of tDCS in patients with ASD, and (3) to determine whether resting-state functional connectivity measures can predict the therapeutic effects of active tDCS in individuals with ASD.\n\nMethods: To assess the therapeutic effects and neural mechanisms of tDCS, 90 adolescents with ASD (age 12-22 years) will receive three stimulation conditions: cathodal tDCS of the left DLPFC, anodal tDCS of the left DLPFC and sham-tDCS with at least a week apart each time. During the active tDCS or sham-tDCS condition, the participants will be administered a computerized test battery (Cambridge Neuropsychological Test Automated Battery, CANTAB®) to evaluate their cognitive function. EEG before and after the tDCS to evaluate the tDCS-induced alteration in their neural activity and functional connectivity.\n\nHypothesis: Drawing together the different evidence linking ASD with cortical hyper-excitability and disordered neural connectivity, as reviewed previously, the investigators hypothesize that, relative to a sham-tDCS condition, active cathodal (inhibitory) and anodal (excitatory) tDCS over the left DLPRC will induce stimulation-linked facilitation of learning and resultant improvement of cognitive functioning in patients with ASD.\n\nIn addition to the therapeutic effects of tDCS, enhanced neural connectivity, as indexed by altered level EEG theta coherence in patients with ASD, will mediate the beneficial effects of tDCS, relative to sham tDCS, on improvements in cognitive function. Moreover, resting-state functional connectivity will moderate the beneficial effects of active tDCS on cognitive function, relative to sham tDCS, such that participants with greater pre-treatment resting state functional connectively will evidence greater\u002Fless response to tDCS, relative to participants receiving sham tDCS.",[130,131,29],"2025-09-18",{"date":254,"type":35},"2025-09-24",{"date":136,"type":35},{"date":257,"type":23},"2027-04",{"name":70,"class":42},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":54,"phases":268,"briefSummary":269,"conditions":270,"keywords":276,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":43},"100607732","shift-hours-impact-on-fatigue-and-tracking-of-eye-dynamics-100607732","NCT07192380","Shift Hours' Impact on Fatigue and Tracking of Eye Dynamics","SHIFTED","Inclusion Criteria:\n\nAssociate radiologists at IMADIS Group\n\n* In their current position for at least one year\n* Working at one of the IMADIS Group on-call centers\n* Performing night shifts during the study period\n* Able to wear an actimeter watch during the study period (it may be removed during certain procedures, but must be put back on afterwards)\n* Having given their free and informed consent to participate in the study\n\nNon- inclusion criteria:\n\n* Leave during the study period\n* Pregnant women, women in labor, or breastfeeding women\n* Subjects wearing glasses or contact lenses\n\nExclusion Criteria:\n\n\\- Having slept more than 6 hours during the night shift",{"count":267,"type":23},40,[56],"The goal of this clinical trial is to learn how night shift-induced sleep debt affects oculomotor patterns, attentional state, and diagnostic performance in emergency radiologists.\n\nThe main questions it aims to answer are:\n\n* Does sleep debt from a night shift alter oculomotor parameters, as eyes movements (speed and amplitude), fixation duration, pupil size?\n* Does a night shift impact radiologists' diagnostic accuracy, attentional state, and perceived fatigue? Researchers will compare radiologists after a night shift (sleep-deprived) with the same radiologists after a night of rest (control) to see if fatigue-related changes affect both visual exploration strategies and diagnostic performance.\n\nParticipants will:\n\n* Perform a guided saccade task assessed by eye tracking (primary endpoint),\n* Read thoracic CT scans (with and without pulmonary embolism cases) to assess diagnostic performance and visual exploration patterns,\n* Undergo EEG recording to measure attentional state,\n* Complete self-report questionnaires on sleepiness and fatigue.",[271,272,273,274,275,29],"Sleep Deprivation","Sleepiness","Eye-Tracking Technology","Radiologists","Tomography",[277,278,279,280,281,282],"Night-Shift","Radiology","performance","Eye-tracking","Fatigue","Eye strain","2025-09-17",{"date":285,"type":35},"2025-09-25",{"date":287,"type":23},"2025-09-15",{"date":289,"type":23},"2026-05-15",{"name":291,"class":117},"IMADIS Technologies et Services",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":54,"phases":302,"briefSummary":303,"conditions":304,"keywords":307,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":4},"100499366","effects-and-mechanisms-of-ras-training-on-upper-limb-movements-in-pd-patients-100499366","NCT05782322","Effects and Mechanisms of RAS Training on Upper-limb Movements in PD Patients","Effects and Neural Mechanisms of Training Involving Rhythmic Auditory Stimulation on Upper-limb Movements in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* (a) idiopathic PD diagnosed by a neurologist based on the Movement Disorders Society clinical diagnostic criteria;\n* (b) the Hoehn and Yahr stage is 2 or 3, meaning that bilateral movement problems or combination with mild postural instability;\n* (c) a score of Montreal Cognitive Assessment (MoCA) is equal to or higher than 21 to ensure that they understand experimental instructions;\n* (d) a score of Edinburgh Handedness Inventory is above 60 to ensure that they are right-handed;\n* (e) types and doses of medications remain unchanged in the past month right before participation.\n* Age- and sex-matched healthy controls who filled the criteria (c) and (d) will be recruited from communities.\n\nExclusion Criteria:\n\n* the presence of medical conditions or diseases that may affect hand movements, vision, or hearing based on self-report.","85 Years",{"count":301,"type":23},72,[56],"Introduction Bradykinesia (i.e., slow movements) is one of the most prominent symptoms of Parkinson's disease (PD) and has a negative impact on quality of life. Rhythmic auditory stimulation (RAS), a widely used and promising treatment technique, has been shown to effectively improve gait speed in PD patients. However, only few studies have explored effects and neural mechanisms of RAS on upper-limb movements. We will conduct two studies to investigate effects and mechanisms of RAS on upper-limb movements in PD patients. The purpose of this study is to examine effects and neural mechanisms of upper-limb movement training involving RAS in PD patients.\n\nMethods This study will recruit patients with PD and healthy controls. This study will randomly assign PD patients into two groups: the PD-RAS group and the PD-noRAS group, and healthy controls into the HC-RAS group and the HC-noRAS group. A 7-day upper-limb training involving RAS (for the PD-RAS group and the HC-RAS group) or without RAS (for the PD-noRAS group and the HC-noRAS group) will be provided. EEG and behavioral assessments will be conducted before and after the first day of training, and after the seven-day training program. Two-way repeated measures analysis of variance will be performed to investigate the group and time effects on upper-limb function and neural activity.\n\nStudy significance The training program will serve as a reference for clinical practitioners who are interested in using RAS in clinical training for PD patients.",[305,306,29],"Acoustic Stimulation","Parkinson Disease",[305,306,308,29],"Movement","2025-04-08",{"date":311,"type":35},"2025-04-10",{"date":313,"type":23},"2025-05-01",{"date":315,"type":23},"2026-03-31",{"name":70,"class":42},{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":328,"conditions":329,"keywords":334,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":43},"100530701","predictive-value-of-neurovascular-coupling-in-infants-with-congenital-heart-disease-100530701","NCT06190210","Predictive Value of Neurovascular Coupling in Infants With COngenital Heart Disease","The Impact of Perioperative Neurovascular Coupling on Outcome in Infants With Congenital Heart Disease.","NICO","Inclusion Criteria:\n\n* CHD warranting a first percutaneous or surgical intervention in the first 6 months, including but not limited to transposition of the great arteries (TGA), univentricular heart (UVH), Tetralogy of Fallot (TOF), coarctation of the aorta (CoA), total abnormal pulmonary venous drainage (TAPVU), Common arterial trunc (TA), large patent ductus arteriosus (PDA) or VSD and AVSD for which treatment is necessary within the first 6 months of life.\n* Treatment provided at the University Hospitals Leuven.\n\nExclusion Criteria:\n\n* Syndromes or proven genetic conditions which are associated with neurological impairment\n* CHD warranting treatment after 6 months of life\n* Suspected or proven metabolic diseases\n* No parental\u002Fguardian consent","6 Months",{"count":327,"type":23},200,"Infants with congenital heart disease (CHD) are at increased risk for delayed neurodevelopment. Multiple etiological explanations have been proposed, as there seems to be a multifactorial interplay of both prenatal and perioperative factors. The main goal of this research project is to focus on peri-operative physiological risk factors in infants with CHD which impair functional brain maturation or elicit brain injury, and subsequently creating a risk model and guidelines for standardized developmental follow-up in this population.\n\nPART 1: investigation of cerebral autoregulation and neurovascular coupling The homeostasis in cerebral blood supply regardless of perfusion pressure, is called Cerebral autoregulation (CAR). Neurovascular coupling (NVC) is the phenomenon in which blood supply increases as a result of increased brain activity in a specific area. At different times in the perioperative phase, these regulatory mechanisms will be estimated based on Electroencephalography (EEG) and Near Infrared Spectroscopy (NIRS), in addition to hemodynamic parameters.\n\nPART 2: cell-free DNA (cfDNA) extraction. Non-invasive monitoring of neuronal degeneration can be performed using cfDNA extraction techniques. Serial measurements of neuronal cfDNA will be used to determine whether and when this neuronal damage has occurred.\n\nPART 3: Prognosis and outcome. These risk factors, supplemented with demographic factors and medications administered, will be combined in an Artificial Intelligence-driven model, thus establishing a risk model for neurodevelopmental outcome. This model will be compared to the current standard-of-care, both structural imaging (ultrasound and MRI) and a clinical developmental assessment at 9 and 24 months of age (Bayley Scales of Infant Development-III).",[330,331,29,332,333],"Congenital Heart Disease","Neurodevelopmental Disorders","Near-Infrared Spectroscopy","Biomarkers",[335,336,337,333,94,338],"Congenital heart disease","Neurodevelopment","Neuromonitoring","NIRS","2025-03-27",{"date":341,"type":35},"2025-04-02",{"date":343,"type":35},"2023-12-01",{"date":345,"type":23},"2027-09-30",{"name":347,"class":42},"Universitaire Ziekenhuizen KU Leuven",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":18,"minAge":355,"maxAge":50,"enrollmentInfo":356,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":358,"conditions":359,"keywords":362,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":43},"100569781","the-eeg-study-under-remimazolam-anesthesia-in-children-100569781","NCT06698705","The EEG Study Under Remimazolam Anesthesia in Children","Electroencephalogram Study in Children Under Remimazolam Anesthesia - a Prospective,Observational Study","Inclusion Criteria:\n\n1\\. aged 1 years-12 years; 2, with American Society of Anesthesiologists (ASA) physical status I or II; 3, children requiring general anesthesia under remimazolam; 4, parents or legal guardians of children who volunteered to participate in the trial; And signed the informed consent form.\n\nExclusion Criteria:\n\n1. Congenital malformation or other genetic conditions that are thought to affect brain development ;\n2. History of severe heart, brain, liver, kidney and metabolic diseases ;\n3. Premature infants (≤32 weeks);\n4. Upper respiratory tract infection in the last two weeks. -","1 Year",{"count":357,"type":23},60,"The effect of Remimazolam on brain electrical activity. Previous studies have shown that in healthy male volunteers, EEG changes during Remimazolam infusion are characterized by an initial increase in the beta band and a later increase in the delta band. When monitoring the depth of anesthesia, the commonly used Bispectral Index in clinical practice was originally developed for propofol. Therefore, studies have shown that the correlation between the depth of sedation of benzodiazepines such as midazolam and Bispectral Index is weak. In contrast, the beta wave ratio is considered a more suitable EEG indicator for monitoring the sedative effect of Remimazolam. The above indicates that Remimazolam has a specific pattern of influence on EEG activity, especially in the regulation of anesthesia depth, with unique characteristics.",[29,360,361],"Remimazolam","Child Neglect",[29,360,363],"children","2025-02-04",{"date":366,"type":35},"2025-02-06",{"date":368,"type":35},"2024-11-22",{"date":370,"type":23},"2025-12-01",{"name":372,"class":42},"Second Affiliated Hospital of Wenzhou Medical University",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":17,"sex":18,"minAge":380,"maxAge":381,"enrollmentInfo":382,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":43},"100560659","the-eeg-study-under-sevoflurane-anesthesia-in-children-100560659","NCT06580028","The EEG Study Under Sevoflurane Anesthesia in Children","Electroencephalogram Study in Children Under Sevoflurane Anesthesia - a Prospective,Observational Study","Inclusion Criteria:\n\n1. aged 1 days#6 years#;\n2. with American Society of Anesthesiologists (ASA) physical status I or II#;\n3. children requiring general anesthesia under sevoflurane;\n4. parents or legal guardians of children who volunteered to participate in the trial; And signed the informed consent form.\n\nExclusion Criteria:\n\n1. Congenital malformation or other genetic conditions that are thought to affect brain development ;\n2. History of severe heart, brain, liver, kidney and metabolic diseases ;\n3. Premature infants (≤32 weeks);\n4. Upper respiratory tract infection in the last two weeks.","1 Day","6 Years",{"count":383,"type":23},280,"Sevoflurane is one of the most commonly used volatile anesthetics in children because of its rapid induction, recovery and recovery properties. Clinical studies using noninvasive brain monitoring have shown that general anesthetics and hypnotics generate electroencephalogram (EEG) oscillations in specific spatial tissues that are fundamentally related to the structure and function of neural circuits. Slow-wave-delta (0.1-4 Hz) oscillations were present in children of all ages, and the advantage of frontal α-wave oscillations appeared at approximately 6 months, began to be consistent at 10 months, and persisted at older ages. Another study, which analyzed EEG under sevoflurane general anesthesia in children aged 0-6 months, found that Theta and alpha wave power decreased with a decrease in sevoflurane concentrations in infants between 4 and 6 months of recovery. However, these studies lack detailed characterization of the neural circuit activity associated with anesthesia, especially at specific developmental ages that are highly correlated with brain plasticity. The aim of this study was to explore electroencephalogram (EEG) of children of different ages under sevoflurane general anesthesia (including anesthesia induction, maintenance and recovery) . By analyzing these EEG data in detail, we hope to be able to better understand the EEG characteristics of children of different ages under sevoflurane anesthesia, and thus develop a neurophysiology pediatric anesthesia status monitoring strategy.",[29,386,361],"Sevoflurane",[386,388,389],"Children","Electroencephalogram",{"date":391,"type":35},"2025-02-07",{"date":393,"type":35},"2024-09-04",{"date":395,"type":23},"2026-09",{"name":372,"class":42},{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":18,"minAge":403,"maxAge":299,"enrollmentInfo":404,"targetDuration":4,"studyType":54,"phases":405,"briefSummary":406,"conditions":407,"keywords":410,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":419,"locationsCount":43},"100559516","effect-of-transcranial-alternating-current-stimulationtacs-for-early-alzheimers-disease-100559516","NCT06565143","Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease","Inclusion Criteria:\n\n1. Subject diagnosed with early Alzheimer's disease or related diseases according to NIA-AA criteria.\n2. Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia.\n3. CDR score ≤ 2.\n4. Subject under treatment by IAChE for at least 3 months.\n5. psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months.\n\nExclusion Criteria:\n\n1. CDR \\> 2\n2. Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).\n3. History of head injury,stroke,or other neurologic disease.\n4. Organic brain defects on T1 or T2 images.\n5. History of seizures or unexplained loss of consciousness.\n6. Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.\n7. Family history of medication refractory epilepsy.\n8. History of substance abuse within the last 6 months.","50 Years",{"count":267,"type":23},[56],"To investigate the clinical effect neural mechanism of transcranial alternating current stimulation in early Alzheimer's disease",[408,29,409],"Transcranial Alternating Current Stimulation","Early Alzheimer's Disease",[408,29,411,409,412,413],"Neuropsychology","Alzheimer's Disease Assessment Scale-Cognitive Subscale","Working Memory","2024-08-19",{"date":416,"type":35},"2024-08-21",{"date":204,"type":35},{"date":34,"type":23},{"name":420,"class":42},"Anhui Medical University",{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":18,"minAge":428,"maxAge":193,"enrollmentInfo":429,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":43},"100555296","pain-perception-measurement-by-eeg-and-nrs-100555296","NCT06510244","Pain Perception Measurement by EEG and NRS","Measuring Pain Perception to the Same Stimulus in Different Patients Using Electroencephalography and Numerical Rate Scale","Inclusion Criteria:\n\n* Males and females\n* Age: 20-60 years.\n* Tooth #8 vital and mature. No history of dentoalveolar trauma.\n* Adequate coronal tooth structure.\n\nExclusion Criteria:\n\n* Chronic periodontitis.\n* Vertical root fracture.\n* Immature teeth.\n* Necrotic teeth.\n* Systemic diseases that affect the healing process.\n* Non restorable teeth.","20 Years",{"count":430,"type":23},100,"Observational study at CDI Cleveland Dental Institute. Investigators will assess the pain perception in one group of patients using two non-invasive methods. First, a numerical rate scale (NRS) and second, a brain wave EEG.",[225,29,433],"Toothache",[435,436,437],"pain perception","Numeric Pain Rating Scale","electroencephalography","2024-07-19",{"date":440,"type":35},"2024-07-22",{"date":442,"type":35},"2024-01-01",{"date":444,"type":23},"2025-04",{"name":446,"class":42},"Cleveland Dental Institute"]